» Articles » PMID: 9306291

Prevalence of DSM-IV Diagnostic Criteria of Insomnia: Distinguishing Insomnia Related to Mental Disorders from Sleep Disorders

Overview
Journal J Psychiatr Res
Specialty Psychiatry
Date 1997 May 1
PMID 9306291
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiological studies of insomnia in the general population have reported high prevalence rates. However, few have applied diagnostic criteria from existing classification systems. Consequently. It is not possible to determine whether subjects suffered from a sleep disorder or whether the insomnia constituted a symptom of a mental disorder. Insomnia and its relationship with other mental disorders was investigated in the general population using DSM-IV criteria. A representative sample of 5622 subjects from the French population were interviewed about their sleep habits over the telephone by lay interviewers. The course and content of interviews were customized by means of the Sleep-Eval knowledge-based system. A total of 18.6% of the sample reported insomnia complaints. The presence of insomnia complaints, lasting for at least one month with daytime repercussions was found for 12.7% of the sample. Subsequently, subjects were classified according to the Sleep Disorder decision-making process proposed by the DSM-IV classification, but without the recourse of polysomnographic recordings. Specific sleep disorder diagnoses were given for 5.6% of the sample, mostly as insomnia related to another mental disorder, primary insomnia was given for 1.3% of the sample. Primary mental disorder diagnoses were supplied for 8.4% of the sample, mostly as generalized anxiety disorder. The results of this investigation emphasize the need to use classifications to determine whether subjects with insomnia complaints suffer from a sleep disorder or whether insomnia constitutes a symptom of some other mental disorder. These distinctions are of utmost importance as they have a bearing on the choice of treatment. Conversely, diagnoses were obtained by lay interviews, which may have caused a lack of recognition and/or discrimination for light or borderline symptomatology.

Citing Articles

Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.

Krystal A, Blier P, Culpepper L, Nierenberg A, Takaesu Y, Kubota N Neuropsychopharmacol Rep. 2024; 45(1):e12509.

PMID: 39632341 PMC: 11666340. DOI: 10.1002/npr2.12509.


Sex differences in sleep deficits in mice with an autism-linked Shank3 mutation.

Medina E, Rempe M, Muheim C, Schoch H, Singletary K, Ford K Biol Sex Differ. 2024; 15(1):85.

PMID: 39468684 PMC: 11514800. DOI: 10.1186/s13293-024-00664-6.


The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial.

Narayan A, Hayley A, Rose S, Di Natale L, Downey L Psychopharmacology (Berl). 2024; 242(2):297-308.

PMID: 39153080 PMC: 11774964. DOI: 10.1007/s00213-024-06674-x.


The Prevalence of Adolescent Social Fears and Social Anxiety Disorder in School Contexts.

Alves F, Figueiredo D, Vagos P Int J Environ Res Public Health. 2022; 19(19).

PMID: 36231757 PMC: 9566153. DOI: 10.3390/ijerph191912458.


Insomnia and related factors in patients with pre-existing psychiatric disorders compared to the general population during the COVID-19 lockdown: Findings from the multicentric COMET study.

DellOsso B, Vigano C, Conti D, Scarpa C, Casati L, Albert U Compr Psychiatry. 2022; 118:152345.

PMID: 35988374 PMC: 9364932. DOI: 10.1016/j.comppsych.2022.152345.